{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:02:30Z","timestamp":1792677750160,"version":"4.5.0"},"reference-count":35,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Although the vast majority of CTCL subtypes are of the CD4+ T-helper cell differentiation phenotype, there is a spectrum of CD8+ variants that manifest wide-ranging clinical, histologic, and phenotypic features that inform the classification of the disease. CD8, like CD4, and cytotoxic molecules (including TIA and granzyme) are readily detectable via IHC staining of tissue and, when expressed on the phenotypically abnormal T-cell population, can help distinguish specific CTCL subtypes. Nonetheless, given that the histopathologic differential for CD8+ lymphoproliferative disorders and lymphomas may range from very indolent lymphomatoid papulosis (LyP) to aggressive entities like CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (AECTCL), CD8 and\/or cytotoxic molecule expression alone is insufficient for diagnosis and is not in itself an indicator of prognosis. We present a review of CTCL subtypes that can demonstrate CD8 positivity: CD8+ mycosis fungoides (MF), LyP type D, subcutaneous panniculitis-like T-cell lymphoma (SPTCL), primary cutaneous gamma\/delta T-cell lymphoma (PCGDTL), CD8+ AECTCL, and acral CD8+ T-cell lymphoproliferative disorder (acral CD8+ TCLPD). These diseases may have different clinical manifestations and distinctive treatment algorithms. Due to the rare nature of these diseases, it is imperative to integrate clinical, histologic, and immunohistochemical findings to determine an accurate diagnosis and an appropriate treatment plan.<\/jats:p>","DOI":"10.3390\/cancers16173087","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T02:34:06Z","timestamp":1725503646000},"page":"3087","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical and Histologic Variants of CD8+ Cutaneous T-Cell Lymphomas"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5116-8266","authenticated-orcid":false,"given":"Madisen A.","family":"Swallow","sequence":"first","affiliation":[{"name":"Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Micevic","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4638-4540","authenticated-orcid":false,"given":"Amanda","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kacie R.","family":"Carlson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine M.","family":"Foss","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation, Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1887-9343","authenticated-orcid":false,"given":"Michael","family":"Girardi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1056\/NEJMra032810","article-title":"The pathogenesis of mycosis fungoides","volume":"350","author":"Girardi","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Carter, J.B., Goyal, A., and McDivitt Duncan, L. (2015). Atlas of Cutaneous Lymphomas, Springer International Publishing.","DOI":"10.1007\/978-3-319-17217-0"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/bjd.20973","article-title":"Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T-cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations: Results of an EORTC Cutaneous Lymphoma Group workshop","volume":"186","author":"Kempf","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/modpathol.2016.240","article-title":"Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: Reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas","volume":"30","author":"Guitart","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/ijd.14689","article-title":"CD8+ cytotoxic mycosis fungoides: A retrospective analysis of clinical features and follow-up results of 29 patients","volume":"59","author":"Sanli","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jdcr.2016.12.003","article-title":"Sudden aggravated CD8+ mycosis fungoides accompanied by hidden adenocarcinoma of the colon","volume":"3","author":"Ahn","year":"2017","journal-title":"JAAD Case Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jaad.2017.05.015","article-title":"CD8+ mycosis fungoides: A low-grade lymphoproliferative disorder","volume":"77","author":"Kantor","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1309\/AJCPOBDP2OQAJ5BR","article-title":"Mycosis fungoides: Report of the 2011 Society for Hematopathology\/European Association for Haematopathology workshop","volume":"139","author":"Song","year":"2013","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jid.2022.08.047","article-title":"CD8+ T Lymphocytes in Hypopigmented Mycosis Fungoides: Malignant Cells or Reactive Clone?","volume":"143","author":"Cao","year":"2023","journal-title":"J. Investig. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaad.2017.05.036","article-title":"Early clinical manifestations of Sezary syndrome: A multicenter retrospective cohort study","volume":"77","author":"Mangold","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1365-2133.2003.05551.x","article-title":"Cutaneous T-cell lymphoma and atopy: Is there an association?","volume":"149","author":"Mehrany","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1634\/theoncologist.2015-0242","article-title":"Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis","volume":"21","author":"Cordel","year":"2016","journal-title":"Oncologist"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaad.2015.09.013","article-title":"Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients","volume":"74","author":"Wieser","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"126","DOI":"10.33160\/yam.2021.02.006","article-title":"Subcutaneous Panniculitis-like T-Cell Lymphoma Without Erythema and Subcutaneous Tumors","volume":"64","author":"Wakumoto","year":"2021","journal-title":"Yonago Acta Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e7143","DOI":"10.1002\/ccr3.7143","article-title":"Subcutaneous panniculitis-like T-cell lymphoma post-mRNA-1273 COVID-19 vaccination","volume":"11","author":"Ukishima","year":"2023","journal-title":"Clin. Case Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jdcr.2022.08.006","article-title":"Subcutaneous panniculitis-like T-cell lymphoma after COVID-19 vaccination","volume":"28","author":"Kreher","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1007\/s10238-023-01210-1","article-title":"Subcutaneous panniculitis-like T-cell lymphoma associated with hemophagocytic lymphohistiocytosis: A systematic review of 63 patients reported in the literature","volume":"23","author":"Ou","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2007-04-087288","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: Definition, classification, and prognostic factors: An EORTC Cutaneous Lymphoma Group Study of 83 cases","volume":"111","author":"Willemze","year":"2008","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjd.13053","article-title":"Systemic corticosteroids for subcutaneous panniculitis-like T-cell lymphoma","volume":"171","author":"Guenova","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clml.2011.06.016","article-title":"Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations","volume":"12","author":"Mehta","year":"2012","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.jdcr.2020.09.018","article-title":"Complete response to romidepsin as monotherapy in treatment-resistant subcutaneous panniculitis-like T-cell lymphoma","volume":"6","author":"Jothishankar","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.path.2021.03.001","article-title":"Gamma\/Delta Phenotype in Primary Cutaneous T-cell Lymphomas and Lymphoid Proliferations: Challenges for Diagnosis and Classification","volume":"14","author":"Huen","year":"2021","journal-title":"Surg. Pathol. Clin."},{"key":"ref_24","first-page":"e35442","article-title":"Primary Cutaneous Gamma-Delta T-cell Lymphoma: A Case Report and Review of Literature","volume":"15","author":"Onukogu","year":"2023","journal-title":"Cureus"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1097\/PAS.0b013e31826a5038","article-title":"Cutaneous \u03b3\u03b4 T-cell lymphomas: A spectrum of presentations with overlap with other cytotoxic lymphomas","volume":"36","author":"Guitart","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/dermatopathology8040054","article-title":"Primary Cutaneous Gamma-Delta T Cell Lymphomas: A Case Series and Overview of the Literature","volume":"8","author":"Maronese","year":"2021","journal-title":"Dermatopathology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jaad.2021.04.081","article-title":"Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sezary syndrome. Part II: Prognosis and management","volume":"85","author":"Oh","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jaad.2011.07.043","article-title":"Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma: Proposed diagnostic criteria and therapeutic evaluation","volume":"67","author":"Nofal","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/cup.13517","article-title":"Primary cutaneous acral CD8+ T-cell lymphoma of the ear: A case report","volume":"46","author":"Ormerod","year":"2019","journal-title":"J. Cutan. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-3-319-99716-2_4","article-title":"Peripheral T-Cell Lymphoma, not Otherwise Specified (PTCL-NOS)","volume":"176","author":"Oluwasanjo","year":"2019","journal-title":"Cancer Treat. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/cup.13967","article-title":"Post-transplant primary cutaneous peripheral T-cell lymphoma not otherwise specified in a pediatric patient","volume":"48","author":"Cardwell","year":"2021","journal-title":"J. Cutan. Pathol."},{"key":"ref_32","first-page":"e125","article-title":"Primary cutaneous peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) simulating periorbital cellulitis","volume":"62","author":"Amoedo","year":"2023","journal-title":"Int. J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.path.2017.01.003","article-title":"Cutaneous Lymphomas with Cytotoxic Phenotype","volume":"10","author":"Calonje","year":"2017","journal-title":"Surg. Pathol. Clin."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.12788\/j.sder.2018.015","article-title":"NK\/T-cell lymphoma, nasal type, \u03b3\u03b4 T-cell lymphoma, and CD8-positive epidermotropic T-cell lymphoma-clinical and histopathologic features, differential diagnosis, and treatment","volume":"37","author":"Geller","year":"2018","journal-title":"Semin. Cutan. Med. Surg."},{"key":"ref_35","unstructured":"Schukow, C., and Ahmed, A. (2023). Dermatopathology, Cutaneous Lymphomas. StatPearls, StatPearls Publishing."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/17\/3087\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:48:50Z","timestamp":1760111330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/17\/3087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":35,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["cancers16173087"],"URL":"https:\/\/doi.org\/10.3390\/cancers16173087","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]}}}